Takeda Pharmaceutical Company Limited
Bispecific antibodies against plasma kallikrein and Factor XII
Last updated:
Abstract:
Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.
Status:
Grant
Type:
Utility
Filling date:
31 Dec 2015
Issue date:
19 Jul 2022